DOD Biotech PCL (BKK:DOD)
Thailand
· Delayed Price · Currency is THB 1.190
0.00 (0.00%)
Apr 25, 2025, 11:33 AM ICT
DOD Biotech PCL Income Statement
Financials in millions THB. Fiscal year is January - December.
Millions THB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 645.38 | 663.61 | 537.16 | 1,015 | 1,077 | Upgrade
|
| Other Revenue | 16.65 | 29.09 | 11.17 | 3.03 | 2.59 | Upgrade
|
| Revenue | 662.04 | 692.71 | 548.33 | 1,018 | 1,080 | Upgrade
|
| Revenue Growth (YoY) | -4.43% | 26.33% | -46.16% | -5.70% | 35.68% | Upgrade
|
| Cost of Revenue | 438.58 | 406.36 | 396.66 | 580.7 | 616.39 | Upgrade
|
| Gross Profit | 223.46 | 286.35 | 151.68 | 437.65 | 463.53 | Upgrade
|
| Selling, General & Admin | 209 | 198.52 | 163.05 | 126.84 | 106.7 | Upgrade
|
| Operating Expenses | 209 | 198.52 | 163.05 | 128.35 | 106.7 | Upgrade
|
| Operating Income | 14.46 | 87.84 | -11.38 | 309.3 | 356.82 | Upgrade
|
| Interest Expense | -3.73 | -5.31 | -7.09 | -6.72 | -6.85 | Upgrade
|
| Interest & Investment Income | 0.73 | 0.25 | 0.11 | 0.25 | 0.22 | Upgrade
|
| EBT Excluding Unusual Items | 11.46 | 82.78 | -18.36 | 302.84 | 350.19 | Upgrade
|
| Gain (Loss) on Sale of Investments | 29.03 | 10.04 | -405.86 | 15.45 | -25.55 | Upgrade
|
| Asset Writedown | - | - | - | -53.23 | - | Upgrade
|
| Pretax Income | 40.49 | 92.82 | -424.23 | 265.06 | 324.64 | Upgrade
|
| Income Tax Expense | 13.32 | 28.3 | -79.11 | 31.96 | 33.87 | Upgrade
|
| Earnings From Continuing Operations | 27.17 | 64.51 | -345.12 | 233.1 | 290.77 | Upgrade
|
| Earnings From Discontinued Operations | -190.99 | -50.94 | -55.37 | -187.44 | -138.74 | Upgrade
|
| Net Income to Company | -163.82 | 13.57 | -400.49 | 45.66 | 152.03 | Upgrade
|
| Minority Interest in Earnings | 4.48 | -6.39 | 2.15 | 4.12 | -10.79 | Upgrade
|
| Net Income | -159.33 | 7.19 | -398.33 | 49.79 | 141.25 | Upgrade
|
| Net Income to Common | -159.33 | 7.19 | -398.33 | 49.79 | 141.25 | Upgrade
|
| Net Income Growth | - | - | - | -64.75% | 62.90% | Upgrade
|
| Shares Outstanding (Basic) | 450 | 435 | 410 | 410 | 410 | Upgrade
|
| Shares Outstanding (Diluted) | 450 | 435 | 410 | 410 | 410 | Upgrade
|
| Shares Change (YoY) | 3.47% | 6.17% | - | - | - | Upgrade
|
| EPS (Basic) | -0.35 | 0.02 | -0.97 | 0.12 | 0.34 | Upgrade
|
| EPS (Diluted) | -0.35 | 0.02 | -0.97 | 0.12 | 0.34 | Upgrade
|
| EPS Growth | - | - | - | -64.45% | 62.67% | Upgrade
|
| Free Cash Flow | 12.31 | 4.72 | -194 | -37.93 | 194.64 | Upgrade
|
| Free Cash Flow Per Share | 0.03 | 0.01 | -0.47 | -0.09 | 0.47 | Upgrade
|
| Gross Margin | 33.75% | 41.34% | 27.66% | 42.98% | 42.92% | Upgrade
|
| Operating Margin | 2.18% | 12.68% | -2.08% | 30.37% | 33.04% | Upgrade
|
| Profit Margin | -24.07% | 1.04% | -72.65% | 4.89% | 13.08% | Upgrade
|
| Free Cash Flow Margin | 1.86% | 0.68% | -35.38% | -3.72% | 18.02% | Upgrade
|
| EBITDA | 71.39 | 156.11 | 48.03 | 371.45 | 427.02 | Upgrade
|
| EBITDA Margin | 10.78% | 22.54% | 8.76% | 36.48% | 39.54% | Upgrade
|
| D&A For EBITDA | 56.93 | 68.27 | 59.41 | 62.15 | 70.2 | Upgrade
|
| EBIT | 14.46 | 87.84 | -11.38 | 309.3 | 356.82 | Upgrade
|
| EBIT Margin | 2.18% | 12.68% | -2.08% | 30.37% | 33.04% | Upgrade
|
| Effective Tax Rate | 32.89% | 30.49% | - | 12.06% | 10.43% | Upgrade
|
| Revenue as Reported | 662.04 | 692.71 | 548.33 | 1,018 | 1,080 | Upgrade
|
Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.